Drug profile · INN
ganirelix acetate
FYREMADEL
ganirelix acetate (FYREMADEL) is a gonadotropin-releasing hormone receptor antagonist. Associated with Amphastar France Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Drug details — ganirelix acetate
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
ganirelix acetate (FYREMADEL) is a gonadotropin-releasing hormone receptor antagonist. Associated with Amphastar France Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Gonadotropin-releasing hormone receptor antagonist
Primary target: Gonadotropin-releasing hormone receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ganirelix acetate?
ganirelix acetate (FYREMADEL) is a gonadotropin-releasing hormone receptor antagonist. Associated with Amphastar France Pharmaceuticals. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ganirelix acetate?
FYREMADEL is a marketed brand name for ganirelix acetate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ganirelix acetate?
ganirelix acetate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.